Lukas Biomedical (ROCO:6814) Cash-to-Debt : 0.27 (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Lukas Biomedical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lukas Biomedical's cash to debt ratio for the quarter that ended in Jun. 2023 was 0.27.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Lukas Biomedical couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Lukas Biomedical's Cash-to-Debt or its related term are showing as below:

ROCO:6814' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.27 Max: 0.4
Current: 0.27

During the past 5 years, Lukas Biomedical's highest Cash to Debt Ratio was 0.40. The lowest was 0.08. And the median was 0.27.

ROCO:6814's Cash-to-Debt is ranked worse than
90.47% of 1522 companies
in the Biotechnology industry
Industry Median: 6.235 vs ROCO:6814: 0.27

Lukas Biomedical Cash-to-Debt Historical Data

The historical data trend for Lukas Biomedical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lukas Biomedical Cash-to-Debt Chart

Lukas Biomedical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

0.40

0.18

0.29

0.36

Lukas Biomedical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash-to-Debt	Get a 7-Day Free Trial					0.08	0.29	0.40	0.36	0.27

Competitive Comparison of Lukas Biomedical's Cash-to-Debt

For the Biotechnology subindustry, Lukas Biomedical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lukas Biomedical's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lukas Biomedical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lukas Biomedical's Cash-to-Debt falls into.

Lukas Biomedical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lukas Biomedical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	40.261	/	(19.199	+	93.223)
	=	0.36

Lukas Biomedical's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	31.408	/	(25.28	+	90.685)
	=	0.27

Lukas Biomedical (ROCO:6814) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lukas Biomedical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lukas Biomedical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lukas Biomedical (ROCO:6814) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lukas Biomedical Inc (ROCO:6814) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Xinyi Road, Da'an District, 3rd Floor, No. 2, Lane 265, Section 4, Taipei, TWN

Website

https://www.lukas-bio.com.tw

Lukas Biomedical Inc is engaged in the research and development of immunotherapy for cancer treatment technologies. It researches on the Memory T cell (LuLym-T) to improve the clinical outcome of cancer treatment.

Lukas Biomedical (ROCO:6814) Headlines

No Headlines